As of 2026-09-16, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -35.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 173.85 mil USD. ORMP's TTM EBITDA according to its financial statements is -4.95 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 12.6x | 8.2x |
| Forward P/E multiples | 11.4x - 15.6x | 14.2x |
| Fair Price | (1.00) - (1.15) | (0.97) |
| Upside | -121.6% - -124.9% | -121.1% |
| Date | EV/EBITDA |
| 2026-09-11 | -35.49 |
| 2026-09-10 | -36.32 |
| 2026-09-09 | -36.48 |
| 2026-09-08 | -38.14 |
| 2026-09-04 | -38.39 |
| 2026-09-03 | -37.72 |
| 2026-09-02 | -38.88 |
| 2026-09-01 | -37.06 |
| 2026-08-31 | -38.47 |
| 2026-08-28 | -38.55 |
| 2026-08-27 | -39.13 |
| 2026-08-26 | -41.12 |
| 2026-08-25 | -40.04 |
| 2026-08-24 | -36.81 |
| 2026-08-21 | -36.73 |
| 2026-08-20 | -36.56 |
| 2026-08-19 | -36.56 |
| 2026-08-18 | -36.48 |
| 2026-08-17 | -34.74 |
| 2026-08-14 | -34.00 |
| 2026-08-13 | -33.17 |
| 2026-08-12 | -32.26 |
| 2026-08-11 | -32.09 |
| 2026-08-10 | -31.68 |
| 2026-08-07 | -32.51 |
| 2026-08-06 | -32.51 |
| 2026-08-05 | -32.67 |
| 2026-08-04 | -33.83 |
| 2026-08-03 | -33.25 |
| 2026-07-31 | -30.60 |
| 2026-07-30 | -31.02 |
| 2026-07-29 | -29.78 |
| 2026-07-28 | -31.43 |
| 2026-07-27 | -31.35 |
| 2026-07-24 | -30.27 |
| 2026-07-23 | -31.35 |
| 2026-07-22 | -30.19 |
| 2026-07-21 | -30.19 |
| 2026-07-20 | -30.85 |
| 2026-07-17 | -30.27 |
| 2026-07-16 | -30.44 |
| 2026-07-15 | -30.52 |
| 2026-07-14 | -30.03 |
| 2026-07-13 | -29.65 |
| 2026-07-10 | -30.36 |
| 2026-07-09 | -31.52 |
| 2026-07-08 | -32.43 |
| 2026-07-07 | -32.51 |
| 2026-07-06 | -34.74 |
| 2026-07-02 | -34.99 |